Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study

[1]  M. J. van den Bent,et al.  Molecular targeted therapies and chemotherapy in malignant gliomas , 2007, Current opinion in oncology.

[2]  Mark R Gilbert,et al.  Chemoradiotherapy in malignant glioma: standard of care and future directions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Raymond,et al.  Lessons learned in the development of targeted therapy for malignant gliomas , 2007, Molecular Cancer Therapeutics.

[4]  K. Hynynen,et al.  Chemotherapy delivery issues in central nervous system malignancy: a reality check. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Johnston,et al.  Detection of cathepsin S cysteine protease in human brain tumour microdialysates in vivo , 2007, British journal of neurosurgery.

[6]  B. O'neill,et al.  Delivery of chemotherapy and antibodies across the blood–brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the eleventh annual blood–brain barrier consortium meeting , 2006, Journal of Neuro-Oncology.

[7]  Susan M. Chang,et al.  Diagnosis and treatment of recurrent high-grade astrocytoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Bigner,et al.  Recent advances in the treatment of malignant astrocytoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Susan A Charman,et al.  Methods to assess drug permeability across the blood‐brain barrier , 2006, The Journal of pharmacy and pharmacology.

[10]  C. Waters,et al.  Pharmacokinetic Considerations in the Treatment of CNS Tumours , 2006, Clinical pharmacokinetics.

[11]  S. Ferrari,et al.  High dose methotrexate in adult patients with osteosarcoma: Clinical and pharmacokinetic results , 2005, Acta oncologica.

[12]  A. Bergenheim,et al.  Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study , 2005, Journal of Neuro-Oncology.

[13]  A. Perkins,et al.  Radionuclide imaging in drug development. , 2004, Current pharmaceutical design.

[14]  U. Ungerstedt,et al.  Microdialysis in neurointensive care. , 2004, Current pharmaceutical design.

[15]  E. Neuwelt.  Mechanisms of Disease: The Blood-Brain Barrier , 2004, Neurosurgery.

[16]  G. Hoizey,et al.  Pharmacokinetics of Methotrexate in the Extracellular Fluid of Brain C6-Glioma After Intravenous Infusion in Rats , 1999, Pharmaceutical Research.

[17]  M. Danhof,et al.  The Use of Intracerebral Microdialysis for the Determination of Pharmacokinetic Profiles of Anticancer Drugs in Tumor-Bearing Rat Brain , 1995, Pharmaceutical Research.

[18]  Determination of Free Extracellular Levels of Methotrexate by Microdialysis in Muscle and Solid Tumor of the Rabbit , 2004, Pharmaceutical Research.

[19]  M. Zucchetti,et al.  Do anticancer agents reach the tumor target in the human brain? , 2004, Cancer Chemotherapy and Pharmacology.

[20]  M. Berger,et al.  Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. , 2002, Journal of neurosurgery.

[21]  Meindert Danhof,et al.  Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting , 2002, Clinical pharmacokinetics.

[22]  M. Siddiqui,et al.  Intracerebral microdialysis and its clinical application: a review. , 2001, Methods.

[23]  R. Egeler,et al.  Chemosensitivity of glioma cells in vitro: a meta analysis , 1999, Journal of Cancer Research and Clinical Oncology.

[24]  O. Gratzl,et al.  Rifampin Concentrations in Various Compartments of the Human Brain: A Novel Method for Determining Drug Levels in the Cerebral Extracellular Space , 1998, Antimicrobial Agents and Chemotherapy.

[25]  T. Lynch,et al.  Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Meindert Danhof,et al.  Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood–brain barrier , 1997, Brain Research Reviews.

[27]  R. Newman,et al.  The Use of Microdialysis in Pharmacokinetics and Pharmacodynamics , 1997, Pharmacotherapy.

[28]  S Saivin,et al.  In vitro and in vivo protein binding of methotrexate assessed by microdialysis. , 1996, International journal of clinical pharmacology and therapeutics.

[29]  J. Gallo,et al.  In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-Bearing rats , 1996, Cancer Chemotherapy and Pharmacology.

[30]  R. Skalak,et al.  Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. , 1995, Cancer research.

[31]  G. Houin,et al.  Protein binding of methotrexate to human albumin and serum. A first derivative spectroscopic analysis. , 1991, Arzneimittel-Forschung.

[32]  O. Major,et al.  Continuous monitoring of blood-brain barrier opening to Cr51-EDTA by microdialysis following probe injury. , 1990, Acta neurochirurgica. Supplementum.

[33]  G. Press,et al.  MR contrast enhancement of intracranial lesions with Gd-DTPA. , 1988, Radiologic clinics of North America.

[34]  R L Ehman,et al.  Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. , 1988, Radiology.